Orbimed Capital, Director: Prelude Therapeutics PRLD Buy · Filed 23/05/24

Trade details

Type: Insider buy
Amount: $4,999,998.75
Shares · price: 869,565 sh · $5.75 a share
Held after: 10,119,756 sh
Stock: Prelude Therapeutics PRLD
Person: Orbimed CapitalDirector
Trade date: 23/05/22
Filed: 23/05/24
Days to filing: 2 days

7 insiders bought this week

Insiders buying this week: 7 insiders
Holding change: +9.4%

Prelude Therapeutics trades, last 26 weeks

What else happened in Prelude Therapeutics around then

Filed or reported within 30 days of the trade day · 23/04/22~23/06/21

Orbimed Capital's recent trades

Orbimed CapitalShareholder
Planned saleEnliven Therapeutics
Planned sale
Enliven Therapeutics
ELVN
$1.4M
29,385 sh
$1.4M
Filed 06/22
Traded 06/22
Orbimed CapitalShareholder
Planned saleEnliven Therapeutics
Planned sale
Enliven Therapeutics
ELVN
$80.3K
1,747 sh
$80.3K
Filed 06/22
Traded 06/22
Orbimed CapitalShareholder
Planned saleEnliven Therapeutics
Planned sale
Enliven Therapeutics
ELVN
$433.9K
10,243 sh
$433.9K
Filed 06/15
Traded 06/15
Orbimed CapitalDirector
BuyPrelude Therapeutics
Buy
Prelude Therapeutics
PRLD
$7.5M
1,689,189 sh
$7.5M
Filed 04/23
Traded 04/21
Orbimed CapitalDirector
BuyPrelude Therapeutics
Buy
Prelude Therapeutics
PRLD
$5M
1,126,126 sh
$5M
Filed 04/23
Traded 04/21

Orbimed Capital, Director — bought $5M of Prelude Therapeutics PRLD · 869,565 sh @ $5.75 | Whalegun